Medullary Thyroid Cancer Clinical Trials

45 clinical trials for Medullary Thyroid Cancer across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Natural History Study of Children and Adults With Medullary Thyroid Cancer — RECRUITING
• Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors — RECRUITING · PHASE1
• Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) — RECRUITING · NA
• Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer — RECRUITING
• Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients — RECRUITING
• 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC — RECRUITING · NA
• Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma — RECRUITING · PHASE4
• A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation — ACTIVE_NOT_RECRUITING · PHASE2
• Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin — COMPLETED · NA
• 211At-MABG in Adults With Advanced Neuroendocrine Cancers — NOT_YET_RECRUITING · PHASE1
• Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment — COMPLETED · PHASE3
• A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer — ACTIVE_NOT_RECRUITING · PHASE4
• A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations — NOT_YET_RECRUITING
• Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer — COMPLETED · NA
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors — COMPLETED · PHASE1
• Thermal Ablation of Cervical Metastases From Thyroid Carcinoma — ACTIVE_NOT_RECRUITING · NA
• Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation — OTHER
• Predictive Factors for Medullary Thyroid Cancer Aggressiveness — COMPLETED
• QUILT-3.006 for Recurrent Medullary Thyroid Cancer — COMPLETED · PHASE2
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations — TERMINATED · PHASE1
• Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma? — COMPLETED
• A Study of TY-1091 in Patients With Advanced Solid Tumors — OTHER · PHASE1
• A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). — WITHDRAWN · PHASE3
• A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study — NOT_YET_RECRUITING
• Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor — OTHER · PHASE1
• Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer — TERMINATED · NA
• Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer — WITHDRAWN · PHASE2
• Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC — OTHER
• Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis — OTHER
• Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer — COMPLETED · PHASE2
• 18F-Fluorocholine PET/CT in Medullary Thyroid Cancer — OTHER
• Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors — TERMINATED · PHASE1
• Nintedanib(BIBF1120) in Thyroid Cancer — COMPLETED · PHASE2
• 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) — TERMINATED
• An Initial Study of Lithium in Patients With Medullary Thyroid Cancer — TERMINATED · PHASE2
• Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients — COMPLETED
• Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib — COMPLETED · PHASE1
• Radiolabeled Molecules for Medullary Thyroid Cancer — OTHER · PHASE4
• Vandetanib Risk Minimisation Effectiveness — COMPLETED
• SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer — COMPLETED · PHASE2
• Expanded Access of Cabozantinib in Medullary Thyroid Cancer — OTHER
• The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer — OTHER · PHASE1

Refine this search